Cargando…

Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer: A Phase 1 Trial

IMPORTANCE: Programmed cell death 1 (PD-1) antibodies have shown substantial survival benefit in patients with advanced non–small cell lung cancer (NSCLC). Toripalimab is a promising and practicable PD-1 antibody; however, its performance in NSCLC has not been established. OBJECTIVES: To assess the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhijie, Ying, Jianming, Xu, Jiachen, Yuan, Pei, Duan, Jianchun, Bai, Hua, Guo, Changyuan, Li, Lin, Yang, Zhenlin, Wan, Rui, Fei, Kailun, Zhao, Zhe, Du, Xinyang, Zhao, Junhui, Lv, Ning, Wang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536589/ https://www.ncbi.nlm.nih.gov/pubmed/33017026 http://dx.doi.org/10.1001/jamanetworkopen.2020.13770

Ejemplares similares

Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer
por: Zhao, Zhe, et al.
Publicado: (2020)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy
por: Zhao, Jie, et al.
Publicado: (2023)

Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment
por: Wang, Chao, et al.
Publicado: (2023)

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
por: Zhang, Lin, et al.
Publicado: (2022)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
por: Wang, Yunchao, et al.
Publicado: (2023)

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer
por: Tian, Yanhua, et al.
Publicado: (2022)

Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer
por: Wang, Hao, et al.
Publicado: (2023)

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer
por: Zhang, Pei, et al.
Publicado: (2020)

Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity
por: Liu, Lihui, et al.
Publicado: (2023)

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
por: Tian, Yanhua, et al.
Publicado: (2020)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
por: Wei, Xiao‐Li, et al.
Publicado: (2020)

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
por: Zhang, Pei, et al.
Publicado: (2022)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis
por: Zhao, Zhe, et al.
Publicado: (2020)

Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer
por: Zuo, Ying, et al.
Publicado: (2022)

Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
por: Lin, Jingrong, et al.
Publicado: (2020)

Paclitaxel/toripalimab: Leucopenia and gastrointestinal reaction: case report
Publicado: (2021)

A prognostic and immunotherapeutic predictive model based on the cell-originated characterization of tumor microenvironment in lung adenocarcinoma
por: Xu, Jiachen, et al.
Publicado: (2023)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Zhao, Ze-Rui, et al.
Publicado: (2021)

Allogeneic dendritic cells induce potent antitumor immunity by activating KLRG1(+)CD8 T cells
por: Wang, Chao, et al.
Publicado: (2019)

Flat dose regimen of toripalimab based on model-informed drug development approach
por: Li, Lili, et al.
Publicado: (2023)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
por: Tao, Ye, et al.
Publicado: (2023)

PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma: A case report
por: Yin, Huaqi, et al.
Publicado: (2022)

Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
por: Du, Xinyang, et al.
Publicado: (2022)

Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers
por: Han, Jiefei, et al.
Publicado: (2021)

Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023)

A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
por: Chen, Rui, et al.
Publicado: (2023)

Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
por: Bu, Yuqing, et al.
Publicado: (2023)

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
por: Zhou, Huanyu, et al.
Publicado: (2022)

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
por: Wang, Zhijie, et al.
Publicado: (2019)

Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma
por: Liu, Xiaomei, et al.
Publicado: (2022)

A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Xing, Wenqun, et al.
Publicado: (2020)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report
por: Wu, Ying, et al.
Publicado: (2023)

Response to toripalimab combined with radiotherapy in advanced non-small cell lung cancer-not otherwise specified: A case report
por: Jin, Yonglong, et al.
Publicado: (2021)

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
por: Cai, Liangliang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c4np6bpj5m8dgmt71o2c8053lv